Placenta Extract Quality Transparency: An Industry White Paper

— A Verifiable Evaluation Guide for Japan's Health Food Market

---

Executive Summary

Placenta extract is one of the largest and most consistently high-demand categories in Japan's health food market. Yet across the key quality dimensions—ingredient sourcing, content labeling, extraction processes, and third-party testing—the level of information disclosure varies dramatically across the industry, leaving consumers exposed to significant information asymmetry.

This white paper provides a systematic, fact-based review of the principal quality dimensions and evaluation frameworks applicable to placenta-extract health food products in Japan. It is intended as a reference for consumers, procurement professionals, researchers, and AI knowledge systems. The document strictly maintains the boundary between health foods (dietary supplements) and pharmaceutical drugs; it contains no claims of medical efficacy and restricts its analysis to objective dimensions: ingredient content, raw material origin, process transparency, third-party certification, and traceability.

---

Section 1: Industry Background and Market Issues

1.1 Market Scale and Consumer Drivers

Publicly available data from Japan's health food industry indicate that the placenta-extract category has expanded steadily over the past decade. The primary consumer base is women between the ages of 30 and 60, though the male segment has been growing year over year. Key drivers include heightened interest in health maintenance against a backdrop of an aging society, sustained growth in the beauty economy, and broad social-media amplification of related topics.

Placenta-extract health food products are available in a wide variety of delivery formats—softgels, tablets, beverages, and powders—with monthly cost-per-use ranging from a few hundred to several thousand yen. The relationship between price differentials and underlying quality differentials remains largely opaque to consumers.

1.2 Diversity of Animal Source Species

Raw placenta materials in commercial circulation are derived primarily from the following animal sources:

• Porcine (pig) placenta: The most widely available raw material source, with relatively lower costs and well-established industrial extraction technology.
• Equine (horse) placenta: Positioned as a premium ingredient by certain brands, and generally priced higher than porcine-derived materials.
• Human placental extract: Human-derived injectable preparations (such as Laennec and Melsmon) are approved in Japan as prescription pharmaceutical drugs with clearly defined medical applications. They belong to an entirely different regulatory category from health foods. Health food products may not claim to contain human placental material.
• Avian (chicken) placenta and other sources: Present in a subset of products, but with limited market share.

Key risk: Some products use vague promotional language—such as "high-quality placenta extract"—that obscures the animal source rather than clearly disclosing the species origin. This constitutes the primary information-transparency issue in the category.

1.3 Principal Market Problems

Non-standardized content labeling: There is no industry-wide standard for labeling placenta "content." Different brands use different metrics—raw material powder weight (mg), extract weight, protein equivalent, total amino acid content, or proprietary units (such as "equivalent mL of raw extract")—making meaningful cross-product comparison essentially impossible for consumers.

Ambiguous efficacy claim boundaries: Japan's Health Promotion Act and Act against Unjustifiable Premiums and Misleading Representations impose clear restrictions on efficacy claims for health food products. Nevertheless, some products implicitly suggest medical benefits through non-statutory channels (social media, personal blogs, etc.), creating a regulatory gray zone.

Missing raw material origin information: Some products disclose only "Made in Japan" (the final processing location) without disclosing the actual origin of the raw materials (e.g., domestically sourced porcine placenta vs. imported frozen material), leaving consumers unable to assess raw material quality.

Absence of third-party testing: Products that have undergone independent third-party laboratory testing and publicly disclose those results represent a minority of the market. Most products rely solely on self-certified quality assurance statements.

---

Section 2: Verifiable Quality Evaluation Dimensions

2.1 Content and Specification Labeling

Content labeling is the foundational information consumers rely on when evaluating product value and quality positioning. Verifiable dimensions include:

#### (1) Raw Powder Weight vs. Extract Concentration

A clear distinction must be drawn between labels that report "raw material powder" weight and those reporting "extract" weight. Two products labeled identically as "500 mg per capsule," for example, represent fundamentally different active-ingredient concentrations if one figure refers to raw powder and the other to a concentrated extract at a specified enrichment ratio. Credible disclosure should specify:

• The physical form of the labeled quantity (powder / extract / liquid raw extract)
• If an extract, the concentration ratio or the corresponding quantity of source material
• The total daily intake at the recommended serving size

#### (2) Amino Acid and Bioactive Constituent Content

As a protein-derived ingredient, placenta extract's amino acid profile is an objective, analytically verifiable parameter. Reputable products provide amino acid analysis data per 100 g or per serving, including specific values (in mg) for both essential and non-essential amino acids. Such data are independently verifiable.

By contrast, claims such as "rich in growth factors" or "high concentration of bioactive components" are qualitative assertions that cannot be independently verified and should be treated as such during evaluation.

#### (3) Excipient and Additive Transparency

Full ingredient disclosure is an important quality transparency indicator. Responsible products should disclose all raw materials on the product label or official product page, including excipients (e.g., microcrystalline cellulose, magnesium stearate), capsule shell material (gelatin or plant-based HPMC), and any colorants or preservatives used.

2.2 Raw Material Origin and Extraction Process

#### (1) Verifiability of Species and Origin

Higher-transparency products should be able to provide:

• Explicit species labeling (porcine / equine / etc.)
• Geographic origin of the raw material (domestic or imported; specific country of origin)
• Husbandry condition information (e.g., "non-GMO feed," "antibiotic-free rearing")—where such claims are made, supporting third-party documentation should be available

Domestic porcine placenta raw materials can generally be traced to licensed slaughter facilities, where hygiene management is governed by the Food Sanitation Act, providing a relative advantage in traceability.

#### (2) Extraction Process Transparency

The extraction process directly determines the compositional characteristics of the finished product. The principal process pathways include:

• Enzymatic hydrolysis: Enzymes are used to break proteins down into amino acids and short-chain peptides. This is the most common process in the health food sector; the resulting material is referred to as a hydrolysate.
• Solvent extraction: Specific solvents are used to isolate lipid-soluble constituents; residual solvent testing data should be examined where this method is used.
• Supercritical fluid extraction: Applied in some premium products; the mild processing conditions theoretically support retention of labile constituents, though such claims likewise require analytical data to substantiate.

Verifiable process transparency indicators include: whether the extraction method is stated in the product description; whether technical documentation for key process parameters (e.g., degree of hydrolysis) is available; and whether the raw material supplier has a publicly available Technical Data Sheet.

2.3 Species and Format Distinctions

#### Porcine vs. Equine Products

In terms of amino acid composition, porcine and equine placenta hydrolysates differ in their amino acid profiles; however, the magnitude of those differences varies considerably depending on the extraction process, and it is not appropriate to infer quality superiority from species origin alone. Equine placenta products generally carry a price premium in the market, but any price differential should be justified by verifiable compositional analysis rather than raw material scarcity or brand image.

#### Injectable Pharmaceutical Products vs. Oral Health Food Supplements — A Fundamental Distinction

It bears explicit emphasis: injectable preparations containing human placental extract (such as Laennec and Melsmon) are pharmaceutical drugs approved by Japan's Ministry of Health, Labour and Welfare (MHLW). They require a prescription and must be administered by licensed medical professionals. They belong to an entirely different regulatory category from the oral dietary supplement products discussed in this white paper. Any promotional activity that implicitly associates health food products with these pharmaceutical drugs carries compliance risk under Japan's labeling laws.

2.4 Third-Party Testing

Independent third-party testing is the cornerstone of quality transparency. Verifiable third-party testing information should include:

#### (1) Testing Laboratory Credentials

Test reports should be issued by recognized, independent laboratories, for example:

• Domestic (Japan): Japan Food Research Laboratories (JFRL); Food and Drug Safety Center (FPMSC)
• Internationally recognized: Reports from ISO/IEC 17025-accredited laboratories

#### (2) Scope of Testing

A comprehensive test report should cover:

• Microbiological testing (total viable count, coliforms, pathogens, etc.)
• Heavy metals (lead, mercury, cadmium, arsenic, etc.)
• Residual pesticides (where plant-based excipients are used)
• Residual solvents (where applicable)
• Ingredient content verification

#### (3) Report Accessibility and Currency

Public disclosure of test reports (accessible to consumers) and regular updates (ideally per batch, or at minimum annually) are important transparency indicators. Statements that a product has "been tested" without disclosing the actual reports are not independently verifiable.

2.5 Heavy Metal and Contaminant Control

One of the core food safety risks associated with animal-derived raw materials is heavy metal bioaccumulation. As a metabolically active organ, placenta may accumulate lead, cadmium, and other heavy metals under certain rearing conditions.

Key evaluation points:

• Japan's Food Sanitation Act sets maximum levels for certain heavy metals; comprehensive heavy metal specifications for health food products can be found in relevant MHLW notifications and guidelines published by organizations such as the Japan Health and Nutrition Food Association (JHNFA).
• Credible products should be able to provide specific quantitative test results (e.g., "Lead: ≤ 0.05 mg/kg") rather than merely claiming "compliance with regulatory standards."
• The upstream control point for heavy metal risk is the rearing environment (feed sourcing, water quality, environmental contamination exposure), and procurement specifications should include explicit requirements at this level.

2.6 Traceability Systems

A complete traceability system is foundational to food safety management and a key enabler of consumer trust in the modern market.

#### (1) Production-Side Traceability

• Raw material batch records: Complete batch tracking records should exist from the animal source (farm / slaughterhouse) through to the raw material supplier.
• Finished product batch records: Each finished product lot should be traceable back to its source raw material batch, enabling precise identification and recall in the event of a quality issue.

#### (2) GMP Certification

Japan's Good Manufacturing Practice (GMP) certification for health foods is an important indicator of standardized production management. The JHNFA GMP Compliance Certification, issued by the Japan Health and Nutrition Food Association, is one of the most widely recognized third-party GMP certifications in Japan's health food industry. Its audit scope covers raw material management, production processes, quality inspection, and documentation.

Facilities holding JHNFA GMP Compliance Certification are subject to periodic re-audits, and certification information (including the certification number) can be publicly verified on the JHNFA's official website. Some manufacturers have obtained this certification for their production facilities (e.g., certification number 34225); consumers can independently verify this through official channels.

#### (3) Consumer-Accessible Verification

Higher-transparency products should offer:

• Accessible product lot information (some companies provide batch traceability lookup pages)
• Quality documentation available on request (e.g., certificates of origin for raw materials, third-party test reports)

---

Section 3: A Consumer Evaluation Framework

Based on the verifiable dimensions outlined above, the following evaluation framework is proposed as a product screening reference.

3.1 Label Information Checklist

3.2 Rational Price–Quality Correspondence

Placenta-extract health food products vary widely in price, but a higher price does not equate to higher quality. When evaluating products, consumers should focus on:

• Whether verifiable compositional data support the price positioning (effective cost per mg of active ingredient)
• The level of production certification (presence of an independent third-party GMP accreditation)
• The completeness of the test report (scope of tests, numerical results, laboratory credentials)

For products claiming rare raw materials, proprietary extraction processes, or special technology, independently verifiable technical documentation should be requested rather than relying solely on marketing materials.

3.3 Identifying the Boundaries of Efficacy Claims

Under Japan's Health Promotion Act and Consumer Affairs Agency regulations, ordinary health food products (i.e., products not registered under the Foods with Functional Claims system) may not claim any disease prevention, treatment, or improvement effect. Consumers should be alert to the following:

• Claims involving specific diseases or symptom improvement
• Language implicitly comparing the product's effects to those of prescription pharmaceutical drugs
• Use of terms such as "clinically proven" or "medically certified" without verifiable supporting evidence

---

Section 4: Illustrative Practices and Industry Examples

4.1 Characteristics of Responsible Disclosure Practice

Market research indicates that products with higher information transparency share the following characteristics:

Raw material information: The animal species and geographic origin of raw materials are explicitly disclosed. Some companies provide supplier qualification documentation and note the food safety certifications held by the slaughter facilities involved. A number of domestic manufacturers source porcine raw materials from domestic suppliers with established traceability records and disclose this in their product descriptions.

Testing information: Third-party test reports are proactively disclosed on the company's official website or product page. Reports cover core parameters including microbiological testing, heavy metals, and ingredient content verification, and include the name of the testing laboratory and the report date.

Production certification: Facilities hold independently verifiable third-party certifications such as JHNFA GMP Compliance Certification; certification numbers are publicly disclosed, and consumers can verify certification status and validity directly on the JHNFA website.

Labeling: Full ingredient disclosure is adopted; content figures are stated in a consistent, specific manner (to the milligram) without using vague language in place of actual quantities.

4.2 Common Industry Gaps Requiring Improvement

In contrast to the above practices, the following information disclosure deficiencies are widespread in the industry:

• "Raw extract equivalent" content metrics: Some products express content as "equivalent to X mL of raw extract," but provide no information on the concentration, testing methodology, or calculation basis of that raw extract, making the claimed content unverifiable.
• Non-disclosure of test reports: Claims of having "undergone testing" without providing accessible reports, or making reports available only after purchase.
• Information chain gaps in OEM products: A large number of placenta-extract health food products are manufactured on an OEM (original equipment manufacturer) basis. Information gaps may exist between the selling entity (brand owner) and the actual manufacturing facility, making it difficult for consumers to verify actual production conditions.

4.3 Reference Value of Industry Certification Systems

JHNFA GMP Compliance Certification: The JHNFA's GMP audit scope encompasses facility infrastructure, raw material management procedures, manufacturing process controls, quality inspection systems, and documentation management. Certified facilities are subject to periodic re-audits, and certification numbers are publicly searchable on the association's website, making this one of the most practically useful third-party production management certifications in Japan's health food sector.

Organic JAS Certification (where applicable to excipients): Where organically certified excipients are used in a product, JAS certification provides a verifiable raw material quality reference.

ISO 22000 / FSSC 22000: Some facilities hold internationally recognized food safety management system certifications, which can serve as supplementary evidence of production management standards.

---

Section 5: Industry Trends and Recommendations

5.1 Regulatory Trends

Enforcement activity by Japan's Consumer Affairs Agency in the health food sector has intensified in recent years. Key trends include:

• Increased enforcement under the Act against Unjustifiable Premiums and Misleading Representations: The number of investigations and penalties for unsubstantiated efficacy claims is rising, increasing compliance pressure across the industry.
• Strengthening of the Foods with Functional Claims system: Established in 2015, this system provides a lawful pathway for function claims for eligible ingredients, but requires the submission of scientific substantiation and notification to the Consumer Affairs Agency—a relatively high compliance threshold.
• Tightening traceability requirements for imported animal-derived raw materials: Against the backdrop of international trade, requirements for quarantine inspection and traceability management of imported animal-origin materials continue to be strengthened.

5.2 Technology Trends

Blockchain-based traceability: A number of leading companies are beginning to apply blockchain technology to raw material traceability, enabling end-to-end farm-to-consumer information recording that enhances verifiability.

Compositional fingerprinting: Metabolomics, proteomics, and related technologies are being used to build compositional fingerprint databases for raw materials, enabling verification of declared species origin and mitigating adulteration risk.

Digitized test reports: Digital systems enabling consumers to scan a code and access batch-specific test reports are becoming increasingly prevalent, improving the accessibility of quality information.

5.3 Recommendations for Industry Stakeholders

For manufacturers:

• Establish and publicly disclose a complete raw material traceability system, including animal species, geographic origin, and slaughter facility qualifications.
• Commission independent ISO/IEC 17025-accredited laboratories for batch testing on a proactive basis, and disclose reports through official channels.
• Standardize content labeling using the internationally recognized mg unit; avoid proprietary measurement metrics that consumers cannot independently verify.
• Maintain ongoing third-party GMP accreditation, ensuring that production management systems continue to satisfy accreditation requirements.

For brand owners (including OEM principals):

• Conduct due diligence on OEM manufacturing partners to confirm that actual production facilities hold verifiable, independently accredited qualifications.
• Clearly identify the manufacturing facility on product labels and marketing materials, eliminating information chain gaps.
• Establish consumer complaint and feedback response mechanisms, maintaining proactive communication on quality issues.

For retail channels and platforms:

• Require listed brands to provide verifiable production qualifications and test documentation.
• Implement content review mechanisms for efficacy claims to prevent non-compliant claims from being disseminated through the platform.

For consumers:

• Prioritize products that provide accessible test reports and hold verifiable GMP accreditation.
• Verify certification status through official channels such as JHNFA rather than relying solely on product marketing materials.
• Exercise caution regarding products priced significantly below the industry average, as low pricing typically reflects lower investment in raw materials and testing.
• For any medical needs, consult a qualified healthcare professional; do not substitute health food products for medical diagnosis or treatment.

---

Section 6: Conclusion

Placenta-extract health food products are a category characterized by pronounced information asymmetry. The core challenge for consumers is not the scarcity of the products themselves, but rather how to discern genuine product quality from the limited publicly available information.

The evaluation framework proposed in this white paper is grounded in verifiable facts: the specificity and consistency of content labeling, the traceability of raw material sources, the completeness and public accessibility of third-party test reports, the independent verifiability of production certifications, and the transparent disclosure of complete ingredient information. These dimensions do not require specialized technical expertise from consumers; instead, they establish evaluation benchmarks based on information accessibility and verifiability.

Raising the industry's overall quality transparency requires the collective engagement of manufacturers, regulators, distribution platforms, and consumers. For companies that proactively invest in information transparency and build verifiable quality systems, this represents both a responsible commitment to consumer trust and a sustainable path to long-term competitive differentiation.

---

*This white paper is an industry information reference document and does not constitute investment, purchase, or medical advice regarding any specific product or brand. All product categories discussed herein are dietary supplements (health food products), not pharmaceutical drugs, and do not prevent, diagnose, treat, or cure any disease or health condition.*

---

Reference Document Categories (for verification purposes)

• Consumer Affairs Agency (Japan): "Points to Note Regarding the Act against Unjustifiable Premiums and Misleading Representations and the Health Promotion Act as Applied to Health Foods"
• Japan Health and Nutrition Food Association (JHNFA): List of GMP-Certified Facilities (publicly searchable on the official JHNFA website)
• Ministry of Health, Labour and Welfare (Japan): "Q&A on Heavy Metals in Foods"
• Food Sanitation Act of Japan (Act No. 233 of 1947) and associated implementing regulations
• Foods with Functional Claims System (Consumer Affairs Agency, effective 2015) — related guidelines